BAJAJ BROKING

Notification
No new Notification messages
One Mobikwik Systems IPO is Open!
Apply for the One Mobikwik Systems IPO through UPI in just minutes.
Open a Free Demat Account
Pay ZERO maintenance charges for the first year, get free stock picks daily, and more.
Trade Now, Pay Later with up to 4x
Never miss a good trading opportunity due to low funds with our MTF feature.
Track Market Movers Instantly
Stay updated with real-time data. Get insights at your fingertips.
NSE BSE
balaxi pharma ltd stock

BALAXI PHARMA LTD Share Price

83.7 -0.13 (-0.15%)
Dec 11 2024 03:29 PM Pharmaceuticals NSE: BALAXI

BALAXI PHARMA LTD Share Price Update

As of the latest trading session, BALAXI PHARMA LTD share price is currently at 83.7, which is down by -0.13 from its previous closing. Today, the stock has fluctuated between 83.52 and 84.50. Over the past year, BALAXI PHARMA LTD has achieved a return of -0.66 %. In the last month alone, the return has been 3.37 %. Read More...

BALAXI PHARMA LTD Performance

Day Range

Low83.52 High84.50
84.17

52 Week Range

Low 74.00 High 151.45
84.17

BALAXI PHARMA LTD Share Price

11309

BALAXI

img img img img
No Data Available

Open Price

84.26

Prev. Close

83.84

Volume (Shares)

6254.00

Total traded value

5.26

Upper Circuit

100.60

Lower Circuit

67.07

Note: The current prices & values are delayed, Login to your account for live updates.

BALAXI PHARMA LTD Fundamentals


(Standalone)

Market Cap (Cr) 91.21
PE Ratio (TTM) 158.81
Book Value / Share 23.05
Beta 1.09
ROE 3.42%
EPS (TTM) 0.53
Dividend Yield 0.00%
Net Profit Qtr (Cr) 1.66

BALAXI PHARMA LTD Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition

Revenue

Net income

Particulars SEP 2024 (Values in Cr)
Revenue 21.16
Operating Expense 20.24
Net Profit 1.66
Net Profit Margin (%) 7.84
Earnings Per Share (EPS) 0.30
EBITDA 2.77
Effective Tax Rate (%) 24.54
Particulars JUN 2024 (Values in Cr)
Revenue 19.03
Operating Expense 17.98
Net Profit 1.38
Net Profit Margin (%) 7.25
Earnings Per Share (EPS) 0.25
EBITDA 2.36
Effective Tax Rate (%) 26.98
Particulars MAR 2024 (Values in Cr)
Revenue 15.90
Operating Expense 16.33
Net Profit -0.58
Net Profit Margin (%) -3.64
Earnings Per Share (EPS) -0.55
EBITDA 0.37
Effective Tax Rate (%) -119.23
Particulars DEC 2023 (Values in Cr)
Revenue 12.70
Operating Expense 12.96
Net Profit 0.49
Net Profit Margin (%) 3.85
Earnings Per Share (EPS) 0.48
EBITDA 1.31
Effective Tax Rate (%) 36.36
Particulars SEP 2023 (Values in Cr)
Revenue 16.55
Operating Expense 16.13
Net Profit 1.18
Net Profit Margin (%) 7.12
Earnings Per Share (EPS) 1.16
EBITDA 2.06
Effective Tax Rate (%) 24.84
Particulars MAR 2024 (Values in Cr)
Revenue 70.20
Operating Expense 67.01
Net Profit 3.65
Net Profit Margin (%) 5.19
Earnings Per Share (EPS) 3.55
EBITDA 7.63
Effective Tax Rate (%) 34.58
Particulars MAR 2023 (Values in Cr)
Revenue 108.14
Operating Expense 92.28
Net Profit 16.22
Net Profit Margin (%) 14.99
Earnings Per Share (EPS) 16.17
EBITDA 23.43
Effective Tax Rate (%) 27.75
Particulars MAR 2022 (Values in Cr)
Revenue 101.29
Operating Expense 84.34
Net Profit 14.67
Net Profit Margin (%) 14.48
Earnings Per Share (EPS) 14.67
EBITDA 20.00
Effective Tax Rate (%) 25.53
Particulars MAR 2021 (Values in Cr)
Revenue 86.87
Operating Expense 68.08
Net Profit 15.13
Net Profit Margin (%) 17.41
Earnings Per Share (EPS) 15.13
EBITDA 20.70
Effective Tax Rate (%) 26.50
Particulars MAR 2020 (Values in Cr)
Revenue 45.63
Operating Expense 36.96
Net Profit 6.50
Net Profit Margin (%) 14.24
Earnings Per Share (EPS) 8.12
EBITDA 9.28
Effective Tax Rate (%) 29.88
Particulars MAR 2024 (Values in Cr)
Book Value / Share 181.31
ROE % -25.94
ROCE % 20.69
Total Debt to Total Equity 0.09
EBITDA Margin 18.75
Particulars MAR 2023 (Values in Cr)
Book Value / Share 169.51
ROE % 31.05
ROCE % 37.25
Total Debt to Total Equity 0.06
EBITDA Margin 17.85
Particulars MAR 2022 (Values in Cr)
Book Value / Share 113.16
ROE % 53.51
ROCE % 59.62
Total Debt to Total Equity 0.04
EBITDA Margin 19.97
Particulars MAR 2021 (Values in Cr)
Book Value / Share 64.98
ROE % 82.26
ROCE % 92.56
Total Debt to Total Equity 0.04
EBITDA Margin 19.41
Particulars MAR 2020 (Values in Cr)
Book Value / Share 27.75
ROE % 39.02
ROCE % 56.54
Total Debt to Total Equity 0.00
EBITDA Margin 19.40
Particulars MAR 2024 (Values in Cr)
Book Value / Share 108.07
ROE % 3.42
ROCE % 5.99
Total Debt to Total Equity 0.13
EBITDA Margin 11.04
Particulars MAR 2023 (Values in Cr)
Book Value / Share 80.35
ROE % 21.62
ROCE % 27.93
Total Debt to Total Equity 0.10
EBITDA Margin 21.71
Particulars MAR 2022 (Values in Cr)
Book Value / Share 57.91
ROE % 29.00
ROCE % 37.15
Total Debt to Total Equity 0.05
EBITDA Margin 19.79
Particulars MAR 2021 (Values in Cr)
Book Value / Share 43.25
ROE % 42.40
ROCE % 55.40
Total Debt to Total Equity 0.05
EBITDA Margin 23.98
Particulars MAR 2020 (Values in Cr)
Book Value / Share 28.11
ROE % 41.10
ROCE % 58.43
Total Debt to Total Equity 0.00
EBITDA Margin 20.25
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 62.29
Total Assets 258.34
Total Liabilities 258.34
Total Equity 201.36
Share Outstanding 10897750
Price to Book Ratio 4.59
Return on Assets (%) -0.92
Return on Capital (%) -1.09
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 28.21
Total Assets 239.66
Total Liabilities 239.66
Total Equity 182.87
Share Outstanding 10181250
Price to Book Ratio 6.60
Return on Assets (%) 19.17
Return on Capital (%) 23.63
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 7.19
Total Assets 176.47
Total Liabilities 176.47
Total Equity 113.16
Share Outstanding 10000000
Price to Book Ratio 6.07
Return on Assets (%) 27.00
Return on Capital (%) 40.8
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 1.66
Total Assets 99.67
Total Liabilities 99.67
Total Equity 64.97
Share Outstanding 10000000
Price to Book Ratio 12.13
Return on Assets (%) 38.25
Return on Capital (%) 55.56
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 4.00
Total Assets 35.97
Total Liabilities 35.97
Total Equity 27.74
Share Outstanding 10000000
Price to Book Ratio 2.63
Return on Assets (%) 16.96
Return on Capital (%) 22
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 44.06
Total Assets 154.36
Total Liabilities 154.36
Total Equity 121.54
Share Outstanding 10897750
Price to Book Ratio 4.59
Return on Assets (%) 2.36
Return on Capital (%) 2.69
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 17.87
Total Assets 129.72
Total Liabilities 129.72
Total Equity 92.10
Share Outstanding 10181250
Price to Book Ratio 6.60
Return on Assets (%) 12.50
Return on Capital (%) 15.77
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 0.84
Total Assets 81.91
Total Liabilities 81.91
Total Equity 57.91
Share Outstanding 10000000
Price to Book Ratio 6.07
Return on Assets (%) 17.90
Return on Capital (%) 24.51
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.47
Total Assets 68.91
Total Liabilities 68.91
Total Equity 43.24
Share Outstanding 10000000
Price to Book Ratio 12.13
Return on Assets (%) 21.95
Return on Capital (%) 32.37
Particulars MAR 2020 (Values in Cr)
Cash & Short Term Investments 3.56
Total Assets 37.90
Total Liabilities 37.90
Total Equity 28.11
Share Outstanding 10000000
Price to Book Ratio 2.63
Return on Assets (%) 17.13
Return on Capital (%) 23.11
Particulars MAR 2024 (Values in Cr)
Net Income 2.01
Cash from Operations 11.54
Cash from Investing -1.04
Cash from Financing 30.25
Net change in Cash 34.07
Free Cash Flow 12.23
Particulars MAR 2023 (Values in Cr)
Net Income 56.92
Cash from Operations 18.16
Cash from Investing -10.56
Cash from Financing 25.51
Net change in Cash 21.02
Free Cash Flow 31.22
Particulars MAR 2022 (Values in Cr)
Net Income 54.52
Cash from Operations 39.73
Cash from Investing -28.44
Cash from Financing -0.16
Net change in Cash 5.53
Free Cash Flow 44.48
Particulars MAR 2021 (Values in Cr)
Net Income 44.32
Cash from Operations 2.59
Cash from Investing -5.97
Cash from Financing 3.64
Net change in Cash -2.32
Free Cash Flow 3.87
Particulars MAR 2020 (Values in Cr)
Net Income 8.79
Cash from Operations -13.29
Cash from Investing -0.18
Cash from Financing 18.09
Net change in Cash 3.87
Free Cash Flow -13.10
Particulars MAR 2024 (Values in Cr)
Net Income 5.58
Cash from Operations 3.24
Cash from Investing 0.46
Cash from Financing 27.55
Net change in Cash 26.18
Free Cash Flow 3.27
Particulars MAR 2023 (Values in Cr)
Net Income 22.45
Cash from Operations -1.65
Cash from Investing -2.29
Cash from Financing 26.39
Net change in Cash 17.03
Free Cash Flow 0.71
Particulars MAR 2022 (Values in Cr)
Net Income 19.69
Cash from Operations 14.57
Cash from Investing -6.87
Cash from Financing -1.63
Net change in Cash 0.37
Free Cash Flow 16.33
Particulars MAR 2021 (Values in Cr)
Net Income 20.59
Cash from Operations 15.89
Cash from Investing -20.03
Cash from Financing 3.49
Net change in Cash -3.08
Free Cash Flow 16.49
Particulars MAR 2020 (Values in Cr)
Net Income 9.18
Cash from Operations -13.62
Cash from Investing -0.28
Cash from Financing 18.09
Net change in Cash 3.44
Free Cash Flow -13.44
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.90 37.87 3.59 505.01 37.54 / 77.70
BLISS GVS PHARMA LTD 155.50 19.46 1.62 1637.91 92.25 / 172.40
CIPLA LTD 1455.65 25.47 4.14 117560.12 1192.85 / 1702.00
FERMENTA BIOTECH LIMITED 414.95 144.08 4.20 1221.24 145.00 / 440.00
Company Name Price P/E P/B Market Cap 52 Week Low/High
AMBALAL SARABHAI ENTERPRISES L 65.90 57.30 11.20 505.01 37.54 / 77.70
AMRUTAJAN HEALTH LTD 753.60 45.84 7.31 2178.71 556.05 / 861.40
ASTRAZENECA PHARMA IND LT 6634.15 128.84 24.41 16585.38 4050.15 / 8139.85
BLISS GVS PHARMA LTD 155.50 20.27 1.59 1637.91 92.25 / 172.40

Technicals

  • EMA & SMA
  • Resistance and Support
  • Price Change Analysis
- redarrow -
red-green-graph indicator
Bullish Moving Averages -
Bearish Moving Averages -
  • 5 Days 83.50
  • 26 Days 83.00
  • 10 Days 82.90
  • 50 Days 88.20
  • 12 Days 82.10
  • 100 Days 95.10
  • 20 Days 82.20
  • 200 Days 123.20
84.12
PIVOT
First Resistance 84.75
Second Resistance 85.37
Third Resistance 86.00
First Support 83.50
Second Support 82.87
Third Support 82.25
RSI 49.85
MACD -1.39
Commodity Channel Index (CCI) 99.56
ADX 10.39
Williams % R -14.17

Over 1 Month

down

3.37

Over 3 Months

down

-25.26

Over 6 Months

down

-27.86

Over 1 Year

down

-0.66

Over 3 Years

down

-6.93

Over 5 Years

down

41.27

BALAXI PHARMA LTD Future

Future: Price

25 May
0 100 200 300 400 500 600

Discount/Premium

25 May
0 1 2 3 4 5 6 7

Active Calls

25 May
0 500 1000 1500 2000 2500 3000

Active Puts

25 Jul
0 500 1000 1500 2000 2500

BALAXI PHARMA LTD Shareholding Pattern

  • Shareholding Summary
  • Historical Promotor Holding
  • Historical MF Holding
  • Historical FII Holding

Holding

Public
17.5
Promoter Holdings
65.99
FII
16.48
DII
0.02
Promoter Shares(Pledge Percentage)
0.0
Name Category Shares Shares%
Balaxi Overseas Private Limited Shareholding of Promoter and Promoter Group 3.5E7 63.4
Elara India Opportunities Fund Limited Public Shareholding 4577717.0 8.29
Mgc Fund Limited Public Shareholding 4521028.0 8.19
Rajasthan Global Securities Private Limited Public Shareholding 1595000.0 2.89
Kunal Mahendra Bhakta Public Shareholding 1028855.0 1.86
Ashish Maheshwari Shareholding of Promoter and Promoter Group 903870.0 1.64
Amol Anand Mantri Public Shareholding 778176.0 1.41
P P Zibi Jose Public Shareholding 609030.0 1.1
Minoshi Maheshwari Shareholding of Promoter and Promoter Group 527900.0 0.96

BALAXI PHARMA LTD

  • Dividend
  • Bonus
  • Split
Ex-Date Dividend Amt. Dividend Type Record Date Instrument Type
2022-07-01 0.5 Final 2022-07-04 Equity shares
Ex-Date Ex-Bonus Ratio
Ex-Date Old FV NEW FV Record Date

Balaxi Pharma Ltd Share Highlights

Balaxi Pharmaceuticals has shown a mixed performance for the quarter ending June 2024. Despite a slight decline in net sales, which dipped by 0.51% year-over-year to Rs 65.62 crore, the company achieved a significant increase in net profit. The net profit soared by 115.67%, reaching Rs 6.48 crore compared to Rs 3.01 crore in the same period last year. Read More... The EBITDA also saw a modest rise of 5.1%, standing at Rs 8.24 crore. This strong profitability, despite flat sales, may positively influence the Balaxi Pharma share price. Investors are likely to view this as a sign of improved operational efficiency and profitability, which could drive future growth. Read Less

Balaxi Pharma Ltd Share Annual Reports

The annual report of Balaxi Pharmaceuticals offers a detailed overview of the company's financial and operational performance over the past fiscal year. It provides insights into revenue streams, cost management, and profitability, which are crucial for understanding the company's overall health and growth prospects. For those tracking the Balaxi Pharma share price, Read More...the annual report is an essential document that sheds light on the company's strategic direction, market positioning, and potential for future growth. It also includes information on the company’s governance practices and sustainability initiatives, providing a comprehensive picture of its operations.  Read Less

Balaxi Pharma Ltd Share Dividend

Balaxi Pharmaceuticals' dividend policy is a key point of interest for investors, particularly given the company's strong net profit growth in the recent quarter. While net sales remained relatively flat, the significant increase in profitability could result in favorable dividend payouts. The Balaxi Pharma share price could be positively impacted by a strong dividend announcement, signaling the company’s commitment to returning value to its shareholders. Investors will be looking closely at the upcoming dividend declaration to gauge the company’s financial stability and its approach to balancing growth with shareholder returns.

About BALAXI PHARMA LTD

Read More
  • Management structure
  • Board of directors
  • Committees of the board of directors

Companies Owned by BALAXI PHARMA LTD

Learn More About Stocks

We have something for everyone

Explore More Investment Options

Stocks

Secure and enhance your financial future today

investment-card-icon

IPOs

Your gateway to future financial opportunities

investment-card-icon

MTF

Explore Buy Now Pay Later and boost your capital by up to 4x  

investment-card-icon

US Stocks

Discover opportunities to invest in elite FAANG stocks

investment-card-icon

Frequently Asked Questions

What is the Balaxi Pharmaceuticals Share price?

Answer Field

The share price of Balaxi Pharmaceuticals Ltd for NSE is ₹ 110.81 and for BSE is ₹ 0.00.

What is the Market Cap of Balaxi Pharmaceuticals Ltd?

Answer Field

The market cap of Balaxi Pharmaceuticals Ltd for NSE is ₹ 1,20.75 Cr. and for BSE is ₹ 0.0 Cr. as of now.

What is the 52W high & 52W low of Balaxi Pharmaceuticals Share?

Answer Field

The 52 Week High and Low of Balaxi Pharmaceuticals Ltd for NSE is ₹ 151.45 and ₹ 79.99 and for BSE is ₹ 0.00 and ₹ 0.00.

How to buy Balaxi Pharmaceuticals Share?

Answer Field

You can trade in Balaxi Pharmaceuticals Ltd shares with Bajaj Broking by opening a Demat Account.

What is one year return for Balaxi Pharmaceuticals Share?

Answer Field

The 1 year returns on the stock has been 16.86%.

What is the P/E ratio of Balaxi Pharma Share in 2024?

Answer Field

As of August 17, 2024, Balaxi Pharmaceuticals' P/E ratio was 13.4. This is a 61% discount to the median range of 34.67 times for its peers.

What is the PB ratio of Balaxi Pharma Share in 2024?

Answer Field

As of August 17, 2024, Balaxi Pharmaceuticals Ltd.'s price-to-book (PB) ratio was 3. This is considered a low PB ratio.

Who is the CEO of Balaxi Pharma Limited?

Answer Field

Ashish Maheshwari is the Chairman and Managing Director of Balaxi Pharmaceuticals Limited. He is also the founder of Balaxi Pharmaceuticals and the Balaxi Group.

When was Balaxi Pharma established?

Answer Field

Balaxi Pharma was established in 1942.

How to buy Balaxi Pharma Share on Bajaj Broking App?

Answer Field

To buy Balaxi Pharma shares on the Bajaj Broking app, follow these steps:

  • Login to the Bajaj Broking App

  • Click on the Search Icon

  • Search “Balaxi Pharma”

  • Click on the BUY icon

  • Place a buy order specifying the desired quantity of shares.

  • Click BUY again to complete the purchase.

Is Balaxi Pharma debt free?

Answer Field

As of August 15, 2024, Balaxi Pharmaceuticals Ltd. (NSE: BALAXI) has negative net debt, meaning it has more cash and short-term investments than debt. Balaxi's debt to equity (D/E) ratio is 0.1, and it has short-term assets that exceed short-term liabilities. Balaxi also has a high Altman Z-score of 4.21, and its long-term assets exceed long-term liabilities. 

No results found

Our Secure Trading Platforms

Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading

Bajaj Broking App Download

8 Lacs+ Users

icon-with-text

4.4+ App Rating

icon-with-text

4 Languages

icon-with-text

₹4700+ Cr MTF Book

icon-with-text
loader